The stock of Abeona Therapeutics Incorporated (NASDAQ:ABEO) registered a decrease of 0.99% in short interest. ABEO’s total short interest was 758,000 shares in September as published by FINRA. Its down 0.99% from 765,600 shares, reported previously. With 86,600 shares average volume, it will take short sellers 9 days to cover their ABEO’s short positions. The short interest to Abeona Therapeutics Incorporated’s float is 4.83%. About 19,579 shares traded hands. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 105.31% since February 8, 2016 and is uptrending. It has outperformed by 88.82% the S&P500.
Abeona Therapeutics, Inc. , formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma products for rare diseases. The company has a market cap of $172.21 million. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. It currently has negative earnings. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases.
Out of 3 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $17 is the highest target while $6.0 is the lowest. The $11.50 average target is 131.85% above today’s ($4.96) stock price. Abeona Therapeutics has been the topic of 3 analyst reports since December 16, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald initiated the stock on September 8 with “Buy” rating. Maxim Group initiated the shares of ABEO in a report on December 16 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.